Can Regular Extra-Virgin Olive Oil Lower Abdominal Obesity, or Is It Just a Marker of a Better Diet?
If two people both eat a Mediterranean-ish diet, but only one reaches for extra-virgin olive oil almost every day, does the waistline notice? A large 2025 Frontiers in Nutrition study suggests it does. In 16,273 adults, regular EVOO intake tracked with a substantially smaller waist, a lower BMI, and a fivefold lower odds of abdominal obesity even after the authors adjusted for their Chrono Med Diet Score. That is not the same as proving causation. But it is a big enough signal to take seriously, especially because the outcome here is central adiposity, not just body weight trivia.
Study Overview
The best part of the design is that it is not pretending to be a clinical trial. The authors used an online CMDS-based survey, then asked a cleaner question than usual: does habitual EVOO use relate to waist size once overall dietary pattern is considered? That matters because abdominal obesity is a better metabolic risk marker than scale weight alone. The survey captured age, sex, height, weight, waist circumference, and dietary/lifestyle information, then tested whether EVOO frequency tracked with anthropometry after adjusting for confounders.
Key Findings: The Waist Signal Was Not Small
The headline result is the logistic regression. Compared with regular EVOO intake, non-regular intake had an adjusted odds ratio of 5.1 for abdominal obesity, with a 95% confidence interval from 3.3 to 6.8 and p < 0.0001. That is a striking association, and it stayed significant after accounting for age, sex, and the overall CMDS score. The waist data were just as hard to ignore: regular users had a mean waist circumference of 89.1 ± 6.7 cm versus 99.4 ± 9.1 cm in sporadic users.
BMI moved too, but less dramatically. Regular users averaged 24.7 ± 3.0 kg/m² versus 26.6 ± 2.9 kg/m² for sporadic users, again with p < 0.001. In other words, the signal was not just “lighter people eat more olive oil.” It was a central adiposity signal, which is the more interesting one clinically.
There is also a nice nuance in the age data. Regular EVOO users were older, not younger, than the sporadic and frequent groups, at 55.9 ± 8.1 years versus 53.9 ± 7.1 and 54.1 ± 7.7. That cuts against the lazy assumption that the healthiest profile always belongs to the youngest group. The authors also showed the pattern in both sexes, and regular intake was more common among women (30.8%) than men (23.9%).
Mechanism: Why Might EVOO Track With a Smaller Waist?
1. The phenolic payload may improve insulin handling
EVOO is not just fat. It delivers hydroxytyrosol, oleuropein derivatives, oleocanthal, and other phenolics that can dampen oxidative stress and inflammatory signaling. That matters because insulin resistance and central fat accumulation feed each other. A dietary pattern that improves insulin sensitivity can plausibly reduce visceral fat storage over time.
2. Better EVOO use may be a marker of better meal structure
The mediation analysis is the real clue here. About 61.9% of the waist association ran through the CMDS, which means regular EVOO use is intertwined with a broader chrono-Mediterranean pattern. The biology may be direct, but the behavior is also part of the story. People who use EVOO consistently may also eat in a more structured, less ultra-processed way.
3. Consistency probably matters more than hero doses
The exposure here was not a giant daily pour. It was about 25 g/day on most days. That hints that metabolic benefit may come from habitual substitution, better fat quality, and repeated exposure to phenolics, not from occasional high-dose use.
Context: How This Fits the Olive Oil Literature
This study does not overturn the field, it sharpens it. Randomized trials on EVOO polyphenols have already pointed to insulin sensitivity, oxidative stress, endothelial function, and atherogenic lipoproteins as plausible benefit zones. What this paper adds is a very human outcome: waist size. That matters because abdominal obesity is the phenotype that often predicts worse cardiometabolic outcomes better than BMI alone.
The most useful comparison is not against a weight-loss drug trial. It is against the usual olive-oil hand-waving. This paper says, in a large real-world sample, that habitual EVOO use looks different from sporadic use even after overall diet quality is accounted for. That is compatible with prior evidence, but more concrete. The result does not prove EVOO is magic. It does support the idea that EVOO is one of the few fats worth treating as an active dietary variable rather than a neutral calorie source.
The direct effect after CMDS adjustment is especially interesting. If EVOO only mattered because it simply indexed a better diet, that direct β would have vanished. It did not. So the safest reading is that regular EVOO is both a marker of a better dietary pattern and a contributor to it.
Practical Takeaway
- • If EVOO is part of your routine, make it routine, not occasional.
- • Think in terms of replacement, not addition: EVOO should usually displace worse fats, not sit on top of the same calories.
- • Waist circumference is the metric to watch, especially if BMI looks “fine” but belly fat is creeping up.
- • For the most plausible benefit, pair EVOO with a broader Mediterranean-style pattern instead of using it in isolation.
Limitations
Cross-sectional design
The study cannot prove that EVOO caused the lower waist circumference.
Self-reported measurements
Diet and anthropometrics came from an online survey, so recall and reporting bias are real concerns.
Missing social covariates
Income, marital status, and smoking were not captured, which leaves room for residual confounding.
No phenolic assay
The survey measured EVOO frequency, not the actual polyphenol content of the oils people used.
Our Take
I like this paper because it asks a better question than most nutrition content does. It does not just ask whether olive oil is “healthy.” It asks whether habitual EVOO use is tied to a clinically relevant fat distribution outcome once overall diet quality is considered. That is a much sharper test.
The effect size is big enough that I would not shrug it off, even though the design is observational. A 10.3 cm waist gap is not a cosmetic difference. It is a cardiometabolic difference. The 5.1 adjusted odds ratio is also hard to ignore, but it should be read as an association, not a prescription dose-response curve.
Bottom line: regular EVOO use looks less like a random food habit and more like a repeatable metabolic behavior. If you want the simplest actionable version of the Mediterranean diet, this is one of the few pieces worth keeping every day.
References
1. Crudele L, et al. Regular extra-virgin olive oil intake independently associates with lower abdominal obesity. Front Nutr. 2025;12:1645230. PMID: 41019557. DOI: 10.3389/fnut.2025.1645230. PubMed →
2. De Matteis C, et al. Improving cardiovascular risk stratification: the role of abdominal obesity in predicting MACEs. Cardiovasc Diabetol. 2025;24:328.
3. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320:C375-C391.
The shortcut
Regular EVOO use looked like a waistline signal, not just a calorie signal, and the strongest clue was the fivefold shift in abdominal obesity odds.
See all research →